Three biosimilar products submitted to the EU for approval have suffered a setback after regulators found 35 GMP deficiencies at Biocon’s fill/finish facility in Bangalore, India.
Arecor has entered a £45m ($56m) agreement to develop once daily injection of Cadila Pharmaceuticals’ basal insulin product using its reformulation technology.
Biocon has been awarded a three-year contract to supply recombinant human insulin formulations made at its Malaysian facility to the country’s Ministry of Health.
The €3m Afrezza has contributed to Sanofi’s revenues since launch is unlikely to subdue growing concerns from commentators surrounding its partner MannKind which developed the inhalable insulin.
Sanofi-Aventis is investing a further $90m in its Chinese manufacturing facility and performing “the world’s largest diabetes genotyping project” in partnership with the Chinese Diabetes Society.
Sanofi-Aventis' disposable insulin pen SoloStar has been launched
across the US for use with the company's 24-hour basal insulin
Lantus (insulin glargine), despite patent infringement claims
emanating from fellow insulin...
Despite numerous media reports of an impending patent infringement
suit, Sanofi-Aventis has yet to formally hear anything from
plaintiff Novo Nordisk, who claims the French firm's SoloStar
insulin pen violates patents covering...